BioXcel Therapeutics Posts Strong Q4 Performance with Beating GAAP EPS Expectations

Tuesday, 12 March 2024, 11:02

The latest financial report from BioXcel Therapeutics shows positive results, with a GAAP EPS of -$0.76 beating estimates by $0.15. Despite a revenue miss of $0.36M at $0.38M, the company demonstrated significant year-over-year growth. With cash and cash equivalents at $65.2 million, BioXcel Therapeutics exhibits resilience in the market.
LivaRava Finance Meta Image
BioXcel Therapeutics Posts Strong Q4 Performance with Beating GAAP EPS Expectations

BioXcel Therapeutics Financial Results

The recent press release from BioXcel Therapeutics (BTAI) unveiled its Q4 financial performance.

Key Highlights:

  • GAAP EPS: -$0.76 (beat by $0.15)
  • Revenue: $0.38M (+58.3% Y/Y, missed by $0.36M)
  • Cash Reserves: $65.2 million

Despite the revenue miss, the company's strong cash position provides stability and growth opportunities.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe